Disarm Therapeutics is creating a new class of therapeutics to treat patients with neurological diseases by preventing axonal degeneration. BioGenerator provided pre-company support through its Grants program, along with introductions and advice. Read the Disarm case study here.
Confluence Discovery Technologies is developing new treatments for inflammatory diseases and cancer. BioGenerator was the first investor in Confluence, working with the founders prior to formation, and invested $1.4M in the company prior to its exit by acquisition in 2017. Read the Confluence case study here.
Benson Hill seeks to solve the world’s greatest challenges by combining plant biology, data analytics and cloud computing. BioGenerator worked with management to relocate the company to St. Louis, and subsequently led the seed round of investment. Read the Benson Hill case study here.
MediBeacon is developing the first real time renal function monitor. BioGenerator worked with the founders to license the assets that formed the company, was its first investor, and subsequently led the seed round of investment. Read the MediBeacon case study here.
SentiAR is improving outcomes in cardiac surgeries through medical holograms. BioGenerator provided pre-company support through the Grants, EIR, Fundamentals, and Grants-2-Business programs. BioGenerator then co-led the company’s seed round. Read the SentiAR case study here.
Unleash Immuno Oncolytics is developing technology for treating cancer. BioGenerator provided pre-company support to Unleash and its sibling company Precision Virologics. BioGenerator Grants, Fundamentals, and Grants2Business were all utilized to help launch these companies. Read more here.